戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 ht chain of hLL1, an internalizing anti-CD74 humanized antibody.
2 ments next to human framework regions in the humanized antibody.
3 ith immunosuppressive drugs or the use of a "humanized" antibody.
4 kg have a half-life similar to that of other humanized antibodies.
5 ut there were no detectable responses to the humanized antibody (0 of 12).
6 by combining these treatments with unlabeled humanized antibodies against CD22 (epratuzumab), CD74 (m
7 mmune modulators (exogenous glucocorticoids, humanized antibodies against cytokines) may decrease dep
8 rowth promoting signals and that therapeutic humanized antibodies against EGFR and HER2 can effective
9  combinations include apolizumab (Hu1D10), a humanized antibody against an epitope of HLA-DR, and IDE
10                              Infliximab is a humanized antibody against tumor necrosis factor alpha (
11 a versatile approach for generating human or humanized antibody agonists with excellent pharmacologic
12                                            A humanized antibody, AK002, targeting Siglec-8 is undergo
13                        Using newly developed humanized antibodies and conditional genetic models, we
14                                         Many humanized antibodies and fusion proteins targeting T-cel
15 ant forms of complement regulatory proteins, humanized antibodies, and synthetic molecules have been
16     As a result, chimeric as well as totally humanized antibodies are currently being evaluated as th
17                             Glycosylation of humanized antibody at Fc-Asn297 significantly affects th
18 oxin were grafted into different CDRs of the humanized antibodies BVK and Synagis (Syn) using both be
19 splay method for optimizing the framework of humanized antibodies by random mutagenesis of important
20 ctions and the development of hypoantigenic "humanized" antibodies by genetic engineering, which then
21         Moreover, it overlooked nanobody and humanized antibody design, hindering therapeutic antibod
22 hough these properties could be blocked by a humanized antibody directed against human endosialin/TEM
23 e (aka TPA) mouse model using temtokibart, a humanized antibody directed against IL-22RA1.
24  and HER2 by chemical FAS inhibitors and the humanized antibody directed against p185(HER2) trastuzum
25                    Starting with a partially humanized antibody, DMB5F3, we created a recombinant chi
26          Intravitreal injection of anti-Scg3 humanized antibody Fab (hFab) inhibited Matrigel-induced
27                         The Fab portion of a humanized antibody (Fab-12; IgG form known as rhuMAb VEG
28 Abs in which the tumor cell specificity of a humanized antibody fragment that recognizes CD3 on T cel
29 ed for the rapid generation of high-affinity humanized antibodies from immunized animals without the
30                                      Indeed, humanized antibodies hAb47 and hAb131 showed similar aff
31                                     Although humanized antibodies have been highly successful in the
32          Genetically engineered chimeric and humanized antibodies have demonstrated activity against
33 e native hormones into different CDRs of the humanized antibody Herceptin.
34  investigated the theranostic potential of a humanized antibody, huAR9.6, targeting fully glycosylate
35 he critical role of designing nanobodies and humanized antibodies in antibody engineering.
36                    Safety studies of a fully humanized antibody in nonhuman primates did not reveal a
37 was shown that the terminal half-life of the humanized antibody in rhesus monkeys is 14-20 days, with
38                                A recombinant humanized antibody-interleukin 2 fusion protein (huKS1/4
39  with cancer, and the immunogenicity of the "humanized" antibody is sufficiently reduced relative to
40 er before or after exposure to MERS-CoV, the humanized antibody may prevent or inhibit MERS-CoV infec
41 ers of PD-L1 inhibition using the engineered humanized antibody MPDL3280A.
42 mulation for our first-in-class FSH-blocking humanized antibody, MS-Hu6, which we propose to move to
43 recombinant antibody technology, which makes humanized antibody or human-mouse chimeric antibody avai
44 odies may be candidates for treatment with a humanized antibody preparation such as daclizumab in the
45                                         This humanized antibody represents an attractive candidate fo
46                              The recombinant humanized antibody (rhuMAb) VEGF has a high affinity for
47 ing lacutamab, a first-in-class anti-KIR3DL2 humanized antibody, selectively killed KIR3DL2+ primary
48 he requirement to construct and analyze each humanized antibody separately.
49                                  RG7356 is a humanized antibody targeting the constant region of CD44
50 allows the generation of high affinity human/humanized antibodies that can be optimized for antibacte
51 rapeutics based on blocking eosinophils with humanized antibodies that neutralize IL-5, a potent eosi
52                                            A humanized antibody that binds to pig and human CD163 was
53                Barzolvolimab (CDX-0159) is a humanized antibody that inhibits KIT activation by SCF a
54 ested the clinical efficacy of eculizumab, a humanized antibody that inhibits the activation of termi
55              In conclusion, H3L2 is an ideal humanized antibody that inhibits tumor growth through ta
56                                Pertuzumab, a humanized antibody that prevents HER2 dimerization and i
57 deleted CC49 (HuCC49DeltaCH2), a recombinant humanized antibody that recognizes the TAG-72 antigen ex
58                       This ADC is based on a humanized antibody that selectively binds with high affi
59                                   huA33 is a humanized antibody that targets the A33 antigen, which i
60                                          For humanized antibodies, the assignment of the frameworks i
61 mework mutations that improve the binding of humanized antibodies to their cognate antigens and may p
62 acid)-conjugated, (111)In- and (90)Y-labeled humanized antibody to CD22, epratuzumab, was studied in
63          We also generate and characterize a humanized antibody to facilitate translation and drug de
64                       We evaluated CDP571, a humanized antibody to tumor necrosis factor, for the tre
65 al antibody technology one can now produce a humanized antibody to virtually any target antigen that
66 this unique "stalk-knob" architecture to the humanized antibody trastuzumab (referred to hereafter by
67  target for personalized treatment using the humanized antibody trastuzumab.
68                            Subsequently, the humanized antibody was de-immunized and site-specific mu
69                              A high affinity humanized antibody was derived that was considerably mor
70  antibody response, two chimeric and several humanized antibodies were constructed for evaluation.
71                                The resulting humanized antibodies were found to retain both high spec
72                                              Humanized antibodies will achieve greater intensity and
73 f graft-framework combinations, resulting in humanized antibodies with improved global properties tha
74 V66-exatecan, a novel ADC composed of V66, a humanized antibody with high affinity for extracellular
75 affinity for antigen relative to the initial humanized antibody with no framework changes.
76 zumab is a glycoengineered, type 2 anti-CD20 humanized antibody with single-agent activity in relapse